Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-10-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司第十届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 17th meeting of the 10th Board of Directors of Jiangsu Sihuan Bio Co., Ltd. It includes voting results on various governance-related proposals such as amendments to company governance systems and internal control policies. The document references the approval of the 2025 third quarter report but does not contain the report itself, only a link to where it can be found. The main content is about board decisions and governance matters, not the full financial report or detailed management discussion. Therefore, this document fits best under Board/Management Information (MANG) as it announces board meeting resolutions and governance changes.
2025-10-24 Chinese
江苏四环生物股份有限公司内幕信息知情人登记及报备制度（2025年10月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '内幕信息知情人登记及报备制度' (Insider Information Insider Registration and Reporting System) issued by 江苏四环生物股份有限公司. It outlines procedures and responsibilities related to insider information management, confidentiality, reporting, and compliance with securities laws and stock exchange regulations. It does not contain financial statements, earnings data, or any form of financial results. It is not an announcement of a report but a governance and compliance document related to insider information control and regulatory adherence. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-10-24 Chinese
江苏四环生物股份有限公司年报信息披露重大差错责任追究制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a '重大差错责任追究制度' which translates to 'Major Error Responsibility Accountability System' related to the annual report information disclosure of Jiangsu Sihuan Bio Co., Ltd. It outlines rules and procedures for accountability in case of major errors in annual report disclosures, including responsibilities, principles, forms of punishment, and legal compliance. It is a governance or internal control policy document rather than an actual annual report, audit report, or announcement of voting results. It does not contain financial data or results but focuses on governance and compliance related to annual report disclosures. Therefore, it fits best under Governance Information (CGR). The document length is short (1587 characters), and it is not an announcement of a report publication but a policy document. Hence, the classification is CGR with high confidence.
2025-10-24 Chinese
江苏四环生物股份有限公司重大信息内部报告制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '重大信息内部报告制度' which translates to 'Major Information Internal Reporting System' and outlines the internal procedures and responsibilities for reporting significant company information. It references laws and regulations related to information disclosure and details the roles of various company officers and departments in managing and reporting material information. The document is a policy or governance document rather than a financial report, earnings release, or announcement. It does not contain financial data, earnings, or voting results. It is not a report publication announcement since it is a substantive internal governance document. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-24 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司2025 年第三季度报告' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It also mentions that the report is unaudited, which is common for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-24 Chinese
江苏四环生物股份有限公司控股子公司管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '控股子公司管理制度' which translates to 'Management System for Controlling Subsidiaries' of Jiangsu Sihuan Bio Co., Ltd. It outlines internal governance, management, financial control, audit supervision, information management, and other operational rules for the company's controlling subsidiaries. There are no financial statements, no earnings data, no voting results, no legal proceedings, no capital changes, no merger or acquisition details, and no regulatory filings or announcements. The document is a detailed internal governance and management policy document, focusing on the company's internal rules and governance practices for subsidiaries. Therefore, it fits best under Governance Information (CGR). The document length is 3402 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Hence, it is not a report publication announcement or regulatory filing.
2025-10-24 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.